"Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients"
NEJM Feb 7
http://www.nejm.org/doi/full/10.1056/NEJMoa1111096"CONCLUSIONS

In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number,NCT00571649.)"

"Effect of Ramipril on Walking Times and Quality of Life Among Patients With Peripheral Artery Disease and Intermittent Claudication"
JAMA Feb 6
http://jama.jamanetwork.com/article.aspx?articleid=1568251
"Conclusions and Relevance
 Among patients with intermittent claudication, 24-week treatment with ramipril resulted in significant increases in pain-free and maximum treadmill walking times compared with placebo. This was associated with a significant increase in the physical functioning component of the SF-36 score."